CClinicalTrials.gg
Status unknownNCT02964000Updated Feb 23, 2017

Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis

An interventional study of Low level 1 Watt and Phoenix Thera-Lase System 42 in Pain, sponsored by Phoenix Thera-lase Systems, LLC. Status unknown at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Phoenix Thera-lase Systems, LLC · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

Hypothesis: Use of high level vs low level cold laser treatments will reduce chronic pain and the need for PRN opioid-containing analgesic medications.

Secondary Hypothesis: High level (vs low level) laser treatments will increase the patients level of physical activity and quality of sleep.

Read the detailed description

Previous studies with low level laser therapy have reported beneficial effects on the level of pain in patients with a variety of chronic pain conditions.

We designed this controlled, double blind, randomized study to determine in the active laser group would have a reduction in the need for 'PRN pain medication'.

Screening Testing

  1. Urine-toxicology screen.
  2. Assessment of level of activity and range of motion and functional capacity evaluation for upper and/ or lower extremity.
  3. Current drug history and use of analgesic medications including both opioid and or non-opioid analgesic medications.
  4. Drug history and current medications along with non-traditional alternative treatments such as (e.g. acupuncture, massage, herbal treatments, etc.)

Protocol Outline After obtaining written informed consent, patients will be asked to complete all the pre-screening and "entry" questionnaires (e.g., SF-36).

11- point Verbal Rating Scale (VRS) for pain at rest and with physical activity (0= none to 10= severe), level of physical activity (0=inactive to 10= fully active), and quality of sleep (0=poor to 10=excellent).

Current analgesic [pain] medications both daily and PRN medications. Randomized into active (Phoenix Thera-Lase [ PTL]) or "Low level" PTL group using a computer generated random numbers table.

Treatment Sessions After obtaining written informed consent for participating in the study and signing the standard HIPPA forms, the patient will be asked to describe the location of their current pain symptoms.

Pre-treatment baseline assessments VRS for pain at rest and with physical activity (e.g. walking, climbing stairs) Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain).

Current opioid and non-opioid analgesic medication usage Clinical opioid withdrawal scale (COWS) at baseline (the COWS will be repeated at the end of the 1st, 2nd, and 3rd week of treatments).

Treatment sessions - Active or low level therapy for 20 - 40 min on Monday, Wednesday, and Friday for 3 weeks.

Post- treatment sessions VRS for pain at rest and with ambulation immediately after each treatment

After the end of 3-week treatment period Repeat pre-screening questionnaires. Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain).

Long-term Follow Up 30-days after the last treatment session, a standardized follow-up questionnaire will be administered.

02

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pain
  • Low level laser therapy
  • Sham
  • Chronic Pain
  • Opioid
  • Physical activity
  • Quality of sleep
03

In context

Chronic Pain

2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.

This study's planned enrollment of 75 is above the median of 60 across 2,161 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

This is the only study on the registry with Phoenix Thera-lase Systems, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female patients
  • 25-65 years of age
  • taking oral opiate-containing analgesic medication on a PRN
  • patient with chronic pain related to an accident, injury or major surgery occurring within the past three years
  • Patients with a potentially treatable pain condition
  • Patient wiling to complete a daily diary for recording their pain score, activity level, quality of sleep and all pain-related medications for the three-week study period

Exclusion criteria

Exclusion Criteria:

  • Use of any opioid-containing pain medications for more than three years
  • History of alcohol or drug abuse, or drug-seeking behavior
  • Previous treatment for drug abuse in detox center or hospital
  • Current psychiatric condition which require centrally- active medications
  • Current excessive use of alcohol
  • Any unstable medical conditions (e.g. coronary artery disease, hepato-renal or pulmonary disease)
  • Patients not capable of consenting for themselves
  • Pregnant women
  • Women of child bearing potential not using acceptable birth control methods.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Low level 1 Watt

    The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

    Device: Low level 1 Watt

  • Experimental
    Phoenix Thera-Lase System 42

    The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

    Device: Phoenix Thera-Lase System 42

  • Experimental
    Phoenix Thera-Lase System 74

    The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

    Device: Phoenix Thera-Lase System 74

Interventions

  • DeviceLow level 1 Watt

    The Phoenix Thera-Lase System will be on 1 watt

    Also known as: 1 watt

  • DevicePhoenix Thera-Lase System 42

    The Phoenix Thera-Lase System will be on 42 watts

    Also known as: 42 Watts

  • DevicePhoenix Thera-Lase System 74

    The Phoenix Thera-Lase System will be on 74 watts

    Also known as: 74 Watts

06

What researchers measure

Primary outcomes

  1. Reduce chronic pain

    Time frame: 1 month

  2. reduce of opioid analgesic dosage.

    Time frame: one month

Secondary outcomes

  1. Level of physical activity

    It will be assessed with a questionnaire

    Time frame: 1 month

  2. Quality of sleep

    It will be assessed with a questionnaire

    Time frame: one month

07

Study locations

1 of 1 sites recruiting
  • Phoenix Thera-Lase Systems
    Dallas, Texas 75231, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02964000
Lead sponsor
Phoenix Thera-lase Systems, LLC
Responsible party
Paul F. White (Professor, Phoenix Thera-lase Systems, LLC) — Principal investigator
First posted
Nov 15, 2016
Start date
Nov 2016
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Feb 23, 2017

Study contacts

Paul F White, PhD, MD
Contact
paul.white@cshs.org
214-770-3775
Ofelia Loani Elvir Lazo, MD
Contact
loanidoc@yahoo.com
310-721-0590
Paul F White, PhD, MD
principal investigator · Phoenix Thera-Lase Systems

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion